Stefan Hasinski, MD
Endocrinology · Phoenix, AZNPI 1194782094
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,094 of the $1,406 with a category attached, or 77.8%. 13 manufacturers reported payments, led by Abbott at 35.4% of the total. Reporting peaked in 2023 at $336 and has fallen 68.7% since, to $105 in 2025.
Across 59 payments — averaging $23.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$497
- Tandem Diabetes Care, Inc.$300
- AbbVie$147
- Amgen$101
- Insulet Corporation$100
- Sanofi-aventis U.S. LLC$78
- plus $183 from 7 others
What the payments were for
- Speaking & faculty fees$30021%
- Food & beverage$1,09478%
- Education$121%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 31 | $497 |
| Tandem Diabetes Care, Inc. | 1 | $300 |
| AbbVie | 2 | $147 |
| Amgen(2 entities) | 6 | $101 |
| Insulet Corporation | 6 | $100 |
| Sanofi-aventis U.S. LLC | 5 | $78 |
| Angiodynamics, Inc. | 1 | $68 |
| Lilly USA, LLC | 2 | $26 |
| Amneal Pharmaceuticals LLC | 1 | $22 |
| Radius Health, Inc. | 1 | $20 |
| Nevro Corp. | 1 | $17 |
| Dexcom, Inc. | 1 | $16 |
| Medtronic | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few endocrinology providers in Arizonato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 241 | $383,494 |
| TrulicityDulaglutide | 131 | $250,493 |
| MounjaroTirzepatide | 116 | $172,118 |
| JardianceEmpagliflozin | 129 | $158,564 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 59 | $119,626 |
| ProliaDenosumab | 67 | $114,537 |
| TradjentaLinagliptin | 83 | $93,671 |
| FarxigaDapagliflozin Propanediol | 76 | $65,688 |
| JanuviaSitagliptin Phosphate | 46 | $52,042 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 20 | $50,823 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 55 | $46,292 |
| Tresiba Flextouch U-200Insulin Degludec | 39 | $40,517 |
| Humalog Kwikpen U-100Insulin Lispro | 94 | $31,133 |
| Tresiba Flextouch U-100Insulin Degludec | 42 | $28,242 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 37 | $27,208 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro, Humalog, Humulin N | $26 | $434,003300 claims |
| AmgenProlia | $101 | $114,53767 claims |
| AbbVieSynthroid | $147 | $20,111231 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $22 | $13,0811,289 claims |
| Sanofi-aventis U.S. LLCLantus | $78 | $8,62831 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few endocrinology providers in Arizonaon file to place this against a meaningful peer group, so we don't.
Other endocrinology in Phoenix
- Richard DolinarPhoenix$411K
- Chet MonderPhoenix$5K
- Radhika VattikutiPhoenix$2K
- Cristian SciuttoPhoenix$0
- Rohit DwivediSurprise$77K
- Mohamad HoraniChandler$0
- Sapna ShahTucson$0
- Freeman FavorsGlendale$0
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.